Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin receptors in the brain, mainly MC4R, to affect sexual desire and arousal. It is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and use in men is off-label and needs clinician oversight 1.
What is PT-141 bremelanotide?
PT-141 is the research name for bremelanotide, a synthetic peptide related to alpha-melanocyte-stimulating hormone, or alpha-MSH. The FDA-approved brand form is Vyleesi, a subcutaneous auto-injector approved in 2019 for certain premenopausal women with hypoactive sexual desire disorder, or HSDD 1.
PT-141 belongs to a drug class called melanocortin receptor agonists. That means it binds to melanocortin receptors, including MC4R and MC3R, which are involved in sexual behavior, appetite, mood, and autonomic body signals in animal and human research 2.
PT-141 came from work on melanotan II, a melanocortin peptide first studied for tanning and pigmentation effects. Researchers noticed sexual arousal effects, then developed bremelanotide as a more targeted medicine for sexual desire disorders 2.
How does PT-141 work in the brain?
Bremelanotide works centrally, meaning it acts in the brain and nervous system. It activates melanocortin receptors, especially MC4R, which can influence dopamine signaling and sexual motivation pathways that include the medial preoptic area in preclinical models 2.
That central action is why PT-141 is different from drugs that mainly change blood flow. In early human studies, melanocortin agonists were linked to erectile responses, and later trials focused on desire and distress in women with HSDD 3, 4.
The same brain-wide mechanism also explains some safety trade-offs. Because melanocortin signaling affects autonomic tone, the FDA label warns about short-term increases in blood pressure and decreases in heart rate after dosing 1.
What are the approved and off-label uses of PT-141?
Vyleesi is approved for one specific group: premenopausal women with acquired, generalized HSDD. The approval does not include men, postmenopausal women, erectile dysfunction, low libido from medication side effects, or low desire caused by relationship conflict or another medical condition 1.
Off-label use means a licensed clinician may consider a medicine for a use not listed on its FDA label when they judge it medically appropriate. PT-141 use in men for erectile dysfunction or low libido is off-label, and the evidence base is smaller than it is for FDA-approved PDE5 inhibitors such as sildenafil and tadalafil 5, 6.
PT-141 for women with HSDD
HSDD means low sexual desire that causes personal distress. In the RECONNECT phase 3 trials, bremelanotide improved sexual desire scores and reduced distress scores compared with placebo in premenopausal women with acquired, generalized HSDD; individual results varied, and nausea was common 3.
The FDA label also notes a clear limitation: Vyleesi is not approved for HSDD in postmenopausal women, men, or people whose low desire is mainly due to another medical or psychiatric condition, medication, or relationship problem 1.
PT-141 for men with ED or low libido
PT-141 has been investigated in men with erectile dysfunction, including early studies of intranasal PT-141 and other melanocortin agonists. Some studies showed erectile responses, but PT-141 is not FDA-approved for men, and modern ED guidelines still center evaluation of cardiovascular risk, medication causes, lifestyle factors, and approved ED therapies 4, 5.
For men, the honest answer is that PT-141 may be discussed in some clinical settings, but it remains off-label. Side effects such as nausea, flushing, headache, and blood pressure changes still matter, especially in men with cardiovascular risk factors 1, 5.
How is PT-141 different from Viagra and Cialis?
PT-141 and PDE5 inhibitors solve different problems. PT-141 acts in the brain on desire and arousal pathways, while Viagra (sildenafil) and Cialis (tadalafil) inhibit phosphodiesterase type 5 to improve nitric-oxide-related blood flow in the penis 6, 7.
That difference matters because low desire and erectile dysfunction can overlap but are not the same. A person can have normal blood flow but low desire, or strong desire but poor erections due to vascular, nerve, medication, or hormone factors 5.
| Feature | PT-141 / bremelanotide | Viagra / sildenafil and Cialis / tadalafil |
|---|---|---|
| Main drug class | Melanocortin receptor agonist; alpha-MSH analogue 1 | PDE5 inhibitors 6, 7 |
| Main site of action | Brain and nervous system; central arousal and desire pathways 2 | Penile blood vessels and smooth muscle; blood-flow pathway 6 |
| FDA-approved use | Acquired, generalized HSDD in premenopausal women as Vyleesi 1 | Erectile dysfunction in adult men 6, 7 |
| Use in men | Off-label; limited evidence compared with approved ED drugs 4, 5 | On-label for ED when appropriate 6, 7 |
| Key safety issue | Nausea, flushing, headache, injection-site reactions, skin darkening, blood pressure rise 1 | Headache, flushing, low blood pressure risk with nitrates, vision or hearing warnings 6, 7 |
How is PT-141 dosed and administered?
Vyleesi labeling describes a 1.75 mg subcutaneous injection given with an auto-injector before anticipated sexual activity. The label also sets frequency limits: not more than one dose within 24 hours and not more than eight doses per month 1.
Those numbers are label information, not a personal dosing plan. Your own health history, blood pressure, heart risk, other medicines, side effects, and goals all affect whether bremelanotide is appropriate at all 1.
Subcutaneous injection
The FDA-approved Vyleesi product is a subcutaneous auto-injector, meaning it is injected under the skin. The label says it is administered at least 45 minutes before anticipated sexual activity 1.
Injection-site reactions can happen. In clinical trial labeling, nausea, flushing, injection-site reactions, headache, and vomiting were among reported adverse reactions 1.
Compounded nasal and injectable forms
Some clinicians and compounding pharmacies discuss compounded bremelanotide via 503A pharmacy pathways, including injectable or nasal forms. Compounded bremelanotide is not FDA-approved, is not the same as Vyleesi, and does not have FDA-evaluated outcomes data for safety or effectiveness.
Nasal delivery has been studied historically in men, but the FDA-approved bremelanotide product is the subcutaneous auto-injector. If a nasal form is discussed, it should be through a licensed prescriber and a state-licensed pharmacy, not a no-prescription peptide vendor 4.
How long it takes to work
The Vyleesi label uses timing before anticipated sexual activity rather than a daily schedule. In real life, response can vary, and side effects such as nausea or flushing may affect whether a person wants to keep using it 1, 3.
What are the side effects and safety risks of PT-141?
Bremelanotide can cause nausea, flushing, injection-site reactions, headache, vomiting, cough, fatigue, hot flush, tingling, dizziness, and nasal symptoms in label data. Nausea was the most common adverse reaction and was a reason some participants stopped treatment 1.
Another important risk is focal hyperpigmentation, which means darker patches of skin, gums, or breast tissue. The FDA label reports that this occurred more often in people with darker skin and with more frequent dosing, and it may not fully resolve 1.
Blood pressure and cardiovascular cautions
PT-141 can cause a temporary increase in blood pressure and a decrease in heart rate after dosing. The FDA label says Vyleesi is contraindicated in people with uncontrolled hypertension or known cardiovascular disease 1.
This is one reason clinician review matters. Sexual symptoms can also be an early sign of cardiometabolic disease, medication side effects, depression, hormone changes, or sleep problems, and ED guidelines recommend a broader health review rather than treating the symptom alone 5.
Who should not take PT-141
- People with uncontrolled high blood pressure or known cardiovascular disease, based on the Vyleesi contraindication 1.
- People whose low desire is mainly caused by another medical condition, psychiatric condition, medication, or relationship problem, because that is outside the labeled HSDD population 1.
- People who are pregnant, planning pregnancy, or breastfeeding should discuss risk carefully; the label includes pregnancy and lactation safety information and does not frame the drug as risk-free 1.
- People using off-label PT-141 for male sexual function should have a licensed clinician review cardiovascular risk, ED causes, medications, and safer approved options 5.
What does the clinical evidence show?
PT-141 has the strongest human evidence in premenopausal women with acquired, generalized HSDD. In the two RECONNECT phase 3 trials, bremelanotide improved sexual desire and reduced distress compared with placebo, but it also caused more adverse events, especially nausea; individual results varied 3.
Earlier phase 2 work also found that bremelanotide improved desire-related outcomes in women with female sexual dysfunction, while adverse events such as nausea and flushing remained important 8.
In men, the evidence is older and smaller. A placebo-controlled study of intranasal PT-141 in men with erectile dysfunction found erectile effects, including in some men with inadequate response to sildenafil, but this did not lead to an FDA-approved male indication 4.
The practical takeaway is balanced: bremelanotide has real clinical trial data for a narrow female HSDD indication, and it has mechanistic and early clinical data in male sexual function. It also has meaningful side effects, cardiovascular cautions, and clear limits on who was studied 1, 3, 5.
How can you get PT-141 safely in 2026?
PT-141 requires a prescription when used as bremelanotide. The safer path is a licensed clinician evaluation, review of blood pressure and cardiovascular history, medication screening, and dispensing through a regulated pharmacy when treatment is appropriate 1, 5.
Be careful with websites selling “research use only” peptides directly to consumers. Those products may bypass medical screening, may not come from a state-licensed pharmacy, and may not have the same sterility, potency, storage, or labeling controls expected in prescription care.
Why gray-market research peptides are risky
The main safety question is not just “brand versus compounded.” It is licensed care versus unlicensed supply. A licensed prescriber can decide whether the symptom pattern fits the medicine, check contraindications, and stop treatment if blood pressure, nausea, pigmentation, or other side effects become unsafe 1.
A state-licensed 503A compounding pharmacy is different from a no-prescription research chemical seller. With any peptide, the safer model is medical evaluation, lawful prescribing, pharmacy dispensing, clear labeling, and follow-up.
Can you get PT-141 through Chia?
Chia does not currently offer PT-141 or bremelanotide in our live catalog. We are saying that plainly because this article is education-first: PT-141 may be appropriate for some patients, but it is not one of the treatments we currently prescribe.
Our current peptide and longevity catalog includes Sermorelin, NAD+, and Glutathione, plus the Foundation Longevity protocol that combines Sermorelin injection, NAD+ injection, and Glutathione injection where clinically appropriate. Those treatments are separate from PT-141 and should not be treated as substitutes for sexual desire disorders.
At Chia, care starts with a short online health questionnaire, then a licensed US provider reviews it and prescribes only when clinically appropriate. Current Chia medications are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door; prescriptions are not guaranteed, and compounded medications are not FDA-approved.
If your main goal is sexual desire, erectile function, pain with sex, hormone symptoms, mood, or relationship distress, the right next step may be a sexual-health clinician, gynecologist, urologist, or primary care provider. If your goals are broader longevity, energy, or metabolic health, you can start with Chia’s online eligibility quiz to see whether our current offerings fit your needs.
Is PT-141 nasal spray the same as the injection?
PT-141 nasal spray is not the same as the FDA-approved Vyleesi auto-injector. The approved product is a subcutaneous injection, while nasal PT-141 has been studied in earlier research and may be discussed in compounded settings, but it does not have the same FDA-approved label 1, 4.
| Form | What it means | Evidence and cautions |
|---|---|---|
| Vyleesi subcutaneous auto-injector | FDA-approved bremelanotide injection under the skin | Approved for acquired, generalized HSDD in premenopausal women; label includes 1.75 mg dosing and safety limits 1 |
| Compounded injectable bremelanotide | A prescription formulation made by a 503A pharmacy when legally and clinically appropriate | Not FDA-approved; outcomes are not established for compounded formulations |
| Compounded nasal bremelanotide | A non-approved nasal route sometimes discussed because intranasal PT-141 was studied historically | Not FDA-approved; older male ED studies do not make it an approved or proven option for broad use 4 |
| Research-use-only PT-141 | Non-prescription peptide sold outside normal pharmacy care | Avoid relying on this route for self-treatment; it lacks clinician screening and regulated prescription follow-up |
What should you ask a clinician before using PT-141?
Bremelanotide is a sexual-health medicine, but the visit should be broader than one prescription. A good evaluation looks at desire, distress, relationship context, blood pressure, cardiovascular history, hormones when relevant, mood, sleep, alcohol use, and medications that can affect libido or erections 5, 9.
- Does my symptom pattern match acquired, generalized HSDD, ED, medication-related low desire, hormone changes, pain, or something else?
- Is my blood pressure controlled, and do I have any cardiovascular reason to avoid bremelanotide? 1
- Which side effects should make me stop and contact the prescribing clinician?
- If use is off-label, what evidence supports that decision and what alternatives should we compare?
- If a compounded form is being considered, which licensed pharmacy is making it and how will follow-up be handled?
Yes. PT-141 is the research name, and bremelanotide is the nonproprietary drug name. Vyleesi is the FDA-approved brand form of bremelanotide for acquired, generalized HSDD in premenopausal women.
Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is not FDA-approved for men, erectile dysfunction, postmenopausal women, or compounded nasal forms.
No. PT-141 acts in the brain through melanocortin receptors involved in desire and arousal. Viagra and Cialis are PDE5 inhibitors that mainly improve blood flow for erections.
Common side effects include nausea, flushing, headache, vomiting, injection-site reactions, dizziness, and tiredness. It can also cause temporary blood pressure increases and, in some people, darker patches of skin or gums.
Use in men is off-label. Some early studies looked at PT-141 in men with erectile dysfunction, but it is not FDA-approved for men. Men should discuss cardiovascular risk, ED causes, and approved treatment options with a licensed clinician.
No. The FDA-approved bremelanotide product is the Vyleesi subcutaneous auto-injector. Nasal PT-141 has been studied historically, but compounded nasal forms are not FDA-approved.
Chia does not currently offer PT-141 or bremelanotide. Chia does offer certain other peptide and longevity treatments, such as sermorelin, NAD+, and glutathione, after licensed-provider review when clinically appropriate.
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health, but any prescription still requires review by a licensed clinician and is never guaranteed.
References
- 1.U.S. Food and Drug Administration. Vyleesi (bremelanotide) injection prescribing information. 2019.
- 2.Cone RD. Studies on the physiological functions of the melanocortin system. Endocrine Reviews. 2006.
- 3.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology. 2019.
- 4.Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women by bremelanotide, a melanocortin receptor agonist. Journal of Sexual Medicine. 2006.
- 5.Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo-controlled crossover study. Journal of Urology. 1998.
- 6.American Urological Association. Erectile Dysfunction: AUA Guideline. 2018.
- 7.U.S. Food and Drug Administration. Viagra (sildenafil citrate) tablets prescribing information. 1998.
- 8.Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Journal of Sexual Medicine. 2016.
- 9.Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions—part II. Journal of Sexual Medicine. 2016.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
